These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 34353680)

  • 1. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
    Melosky B; Wheatley-Price P; Juergens RA; Sacher A; Leighl NB; Tsao MS; Cheema P; Snow S; Liu G; Card PB; Chu Q
    Lung Cancer; 2021 Oct; 160():136-151. PubMed ID: 34353680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
    Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
    J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
    Benjamin DJ; Haslam A; Gill J; Prasad V
    Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis.
    Chen J; Lu W; Chen M; Cai Z; Zhan P; Liu X; Zhu S; Ye M; Lv T; Lv J; Song Y; Wang D
    Ther Adv Med Oncol; 2024; 16():17588359231225036. PubMed ID: 38420602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Path Less Traveled: Targeting Rare Driver Oncogenes in Non-Small-Cell Lung Cancer.
    Lim SM; Lee JB; Oya Y; Nutzinger J; Soo R
    JCO Oncol Pract; 2024 Jan; 20(1):47-56. PubMed ID: 37733983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE; Gandhi L; Costa DB
    Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapeutic options in early and metastatic NSCLC-overview.
    Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
    Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
    Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG
    Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
    Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
    [No Abstract]   [Full Text] [Related]  

  • 12. VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
    Watanabe H; Ichihara E; Kayatani H; Makimoto G; Ninomiya K; Nishii K; Higo H; Ando C; Okawa S; Nakasuka T; Kano H; Hara N; Hirabae A; Kato Y; Ninomiya T; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
    Cancer Sci; 2021 May; 112(5):1853-1864. PubMed ID: 33410241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance Mechanisms to Targeted Therapies in
    McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
    Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.
    Rebuzzi SE; Zullo L; Rossi G; Grassi M; Murianni V; Tagliamento M; Prelaj A; Coco S; Longo L; Dal Bello MG; Alama A; Dellepiane C; Bennicelli E; Malapelle U; Genova C
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current Status and Future Perspectives of Molecular Targeted Therapies for Lung Cancer].
    Suda K; Mitsudomi T
    Kyobu Geka; 2022 Jan; 75(1):53-66. PubMed ID: 35249077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers.
    Tan AC; Itchins M; Khasraw M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.